JP2019506159A - Ｄ因子を阻害するための組成物および方法 - Google Patents

Ｄ因子を阻害するための組成物および方法 Download PDF

Info

Publication number
JP2019506159A
JP2019506159A JP2018538551A JP2018538551A JP2019506159A JP 2019506159 A JP2019506159 A JP 2019506159A JP 2018538551 A JP2018538551 A JP 2018538551A JP 2018538551 A JP2018538551 A JP 2018538551A JP 2019506159 A JP2019506159 A JP 2019506159A
Authority
JP
Japan
Prior art keywords
aptamer
factor
complement factor
cases
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018538551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506159A5 (cg-RX-API-DMAC7.html
Inventor
カール エリクソン，
カール エリクソン，
クリストファー ピー． ルスコーニ，
クリストファー ピー． ルスコーニ，
ケビン ジー． マクルール，
ケビン ジー． マクルール，
Original Assignee
ヴィトリサ セラピューティクス， インコーポレイテッド
ヴィトリサ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィトリサ セラピューティクス， インコーポレイテッド, ヴィトリサ セラピューティクス， インコーポレイテッド filed Critical ヴィトリサ セラピューティクス， インコーポレイテッド
Publication of JP2019506159A publication Critical patent/JP2019506159A/ja
Publication of JP2019506159A5 publication Critical patent/JP2019506159A5/ja
Priority to JP2022039070A priority Critical patent/JP2022078283A/ja
Priority to JP2023220791A priority patent/JP2024029136A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018538551A 2016-01-20 2017-01-20 Ｄ因子を阻害するための組成物および方法 Pending JP2019506159A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022039070A JP2022078283A (ja) 2016-01-20 2022-03-14 Ｄ因子を阻害するための組成物および方法
JP2023220791A JP2024029136A (ja) 2016-01-20 2023-12-27 Ｄ因子を阻害するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662281092P 2016-01-20 2016-01-20
US62/281,092 2016-01-20
US201662297095P 2016-02-18 2016-02-18
US62/297,095 2016-02-18
PCT/US2017/014458 WO2017127761A1 (en) 2016-01-20 2017-01-20 Compositions and methods for inhibiting factor d

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022039070A Division JP2022078283A (ja) 2016-01-20 2022-03-14 Ｄ因子を阻害するための組成物および方法
JP2023220791A Division JP2024029136A (ja) 2016-01-20 2023-12-27 Ｄ因子を阻害するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2019506159A true JP2019506159A (ja) 2019-03-07
JP2019506159A5 JP2019506159A5 (cg-RX-API-DMAC7.html) 2020-02-27

Family

ID=59362699

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018538551A Pending JP2019506159A (ja) 2016-01-20 2017-01-20 Ｄ因子を阻害するための組成物および方法
JP2022039070A Pending JP2022078283A (ja) 2016-01-20 2022-03-14 Ｄ因子を阻害するための組成物および方法
JP2023220791A Pending JP2024029136A (ja) 2016-01-20 2023-12-27 Ｄ因子を阻害するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022039070A Pending JP2022078283A (ja) 2016-01-20 2022-03-14 Ｄ因子を阻害するための組成物および方法
JP2023220791A Pending JP2024029136A (ja) 2016-01-20 2023-12-27 Ｄ因子を阻害するための組成物および方法

Country Status (8)

Country Link
US (4) US10174325B2 (cg-RX-API-DMAC7.html)
EP (1) EP3405577B8 (cg-RX-API-DMAC7.html)
JP (3) JP2019506159A (cg-RX-API-DMAC7.html)
CN (1) CN108934169A (cg-RX-API-DMAC7.html)
AU (3) AU2017210042B2 (cg-RX-API-DMAC7.html)
CA (1) CA3011819A1 (cg-RX-API-DMAC7.html)
GB (1) GB2553252B (cg-RX-API-DMAC7.html)
WO (1) WO2017127761A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009435A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Ether compounds for treatment of complement mediated disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
WO2018136831A1 (en) * 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Pseudoknot compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
MX2019010381A (es) 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2019022986A1 (en) * 2017-07-24 2019-01-31 Vitrisa Therapeutics, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
AU2019406830A1 (en) 2018-12-17 2021-07-08 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2020146731A1 (en) * 2019-01-11 2020-07-16 Drive Therapeutics Llc Compositions and methods for inhibiting vascular endothelial growth factor
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US20220395557A1 (en) * 2019-10-23 2022-12-15 Gemini Therapeutics Sub, Inc. Methods for treating patients having cfh mutations with recombinant cfh proteins
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
US20250129371A1 (en) * 2023-10-11 2025-04-24 Regeneron Pharmaceuticals, Inc. Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528047A (ja) * 2007-05-23 2010-08-19 ジェネンテック， インコーポレイテッド 補体が関係している眼の状態の予防および治療
JP2011521623A (ja) * 2008-04-28 2011-07-28 ジェネンテック， インコーポレイテッド ヒト化抗ｄ因子抗体とその用途
JP2013509866A (ja) * 2009-11-04 2013-03-21 ジェネンテック， インコーポレイテッド Ｄ因子および抗ｄ因子抗体の共結晶構造
WO2015168468A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
WO1998055471A1 (en) 1997-06-03 1998-12-10 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
AU1252099A (en) 1997-11-26 1999-06-15 Medical Research Council Improved selex procedure and an anti-cd4 aptamer
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
DK1265929T3 (da) 2000-03-23 2009-11-16 Genentech Inc Anti-C2/C2a-inhibitorer til komplement aktivering
EP1594541A4 (en) 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
JP5137053B2 (ja) 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP1861114B1 (en) 2005-03-11 2011-02-02 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
JP5707024B2 (ja) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
BRPI0620249A2 (pt) 2005-12-22 2011-11-08 Alcon Res Ltd inibidores de c3-convertase para prevenção e tratamento de degeneração macular correlacionada à idade em pacientes com riscos alternativos do fator h de complemento
DE602006014026D1 (de) 2005-12-22 2010-06-10 Opko Ophthalmics Llc Zusammensetzungen und verfahren zur regulierung eines komplementsystems
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
CN104623692A (zh) 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
US8790924B2 (en) 2006-10-19 2014-07-29 Duke University Reversible platelet inhibition
DK2097455T3 (en) 2006-11-02 2014-12-15 Genentech Inc HUMANIZED ANTI-FACTOR D ANTIBODIES
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
KR20100014486A (ko) * 2007-04-30 2010-02-10 알콘 리서치, 리미티드 보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료
US20090092980A1 (en) 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
GB0718737D0 (en) 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
UY31520A1 (es) 2007-12-11 2009-08-03 Proteinas de union a antigenos
US10632170B2 (en) 2008-02-19 2020-04-28 The Trustees Of The University Of Pennsylvania Administration of compstatin to an individual for the treatment of a tumor
US8940299B2 (en) 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
PL2262831T3 (pl) 2008-03-03 2015-08-31 Novelmed Therapeutics Inc Przeciwciała przeciwko properdynie
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
EP2159286A1 (en) 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Method for obtaining oligonucleotide aptamers and uses thereof
US20110160636A1 (en) 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
AU2010248380B2 (en) 2009-05-15 2013-12-19 Nec Solution Innovators, Ltd. Aptamer that recognizes peptide
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9278108B2 (en) 2009-07-16 2016-03-08 Nec Solution Innovators, Ltd. HMGB1 binding nucleic acid molecule and applications thereof
WO2011017229A2 (en) 2009-08-06 2011-02-10 Tufts - New England Medical Center Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
JP2013544512A (ja) 2010-11-01 2013-12-19 ジェネンテック， インコーポレイテッド 多遺伝子スコアを用いた後期加齢性黄斑変性症への進行の予測
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
US10966945B2 (en) 2011-08-01 2021-04-06 Aurin Biotech Inc. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
AU2012317323B2 (en) 2011-09-28 2017-10-05 Fujimoto Pharmaceutical Corporation NGF aptamer and application thereof
US9316647B2 (en) 2011-12-30 2016-04-19 Somalogic, Inc. Aptamers and diagnostic methods for detecting the EGF receptor
NZ712727A (en) 2013-03-14 2017-05-26 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
AP2016009435A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Ether compounds for treatment of complement mediated disorders
TWI623617B (zh) 2014-08-29 2018-05-11 國立清華大學 對卵巢癌具有專一性之適合體及其應用
JP2018535679A (ja) 2015-11-19 2018-12-06 ベース ペア バイオテクノロジーズ，インク． 標的分子の高感度検出のための方法及び材料
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
EP3405575A4 (en) 2016-01-20 2019-06-26 Vitrisa Therapeutics, Inc. PROCESS FOR IMPROVED APTAMER SELECTION
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018136831A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Pseudoknot compositions and methods for inhibiting factor d
WO2019022986A1 (en) 2017-07-24 2019-01-31 Vitrisa Therapeutics, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528047A (ja) * 2007-05-23 2010-08-19 ジェネンテック， インコーポレイテッド 補体が関係している眼の状態の予防および治療
JP2011521623A (ja) * 2008-04-28 2011-07-28 ジェネンテック， インコーポレイテッド ヒト化抗ｄ因子抗体とその用途
JP2013509866A (ja) * 2009-11-04 2013-03-21 ジェネンテック， インコーポレイテッド Ｄ因子および抗ｄ因子抗体の共結晶構造
WO2015168468A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING, vol. 112, no. 8, JPN6020049747, 2015, pages 1506 - 1522, ISSN: 0004776888 *

Also Published As

Publication number Publication date
HK1251610A1 (zh) 2019-02-01
JP2022078283A (ja) 2022-05-24
CN108934169A (zh) 2018-12-04
US20180051287A1 (en) 2018-02-22
AU2023202548A1 (en) 2023-06-01
EP3405577A1 (en) 2018-11-28
AU2021202392A1 (en) 2021-05-20
WO2017127761A1 (en) 2017-07-27
EP3405577B8 (en) 2023-02-15
US10174325B2 (en) 2019-01-08
GB201718801D0 (en) 2017-12-27
AU2017210042B2 (en) 2021-01-21
AU2017210042A1 (en) 2018-07-26
US11274307B2 (en) 2022-03-15
GB2553252A (en) 2018-02-28
JP2024029136A (ja) 2024-03-05
US20190161755A1 (en) 2019-05-30
GB2553252A8 (en) 2018-03-14
EP3405577B1 (en) 2022-12-14
EP3405577A4 (en) 2019-09-11
AU2021202392B2 (en) 2023-02-02
US20200392502A1 (en) 2020-12-17
US20250197868A1 (en) 2025-06-19
GB2553252B (en) 2019-07-31
CA3011819A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
US20250197868A1 (en) Compositions and methods for inhibiting factor d
RU2477137C2 (ru) Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
US11466276B2 (en) Stem-loop compositions and methods for inhibiting factor D
WO2018136831A1 (en) Pseudoknot compositions and methods for inhibiting factor d
WO2020247850A1 (en) Compositions and methods for inhibiting angiopoietin-2
WO2019022986A1 (en) NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
US20220098591A1 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growtn factor
AU2022202115A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20210230599A1 (en) Stem-loop compositions and methods for inhibiting interleukin-8
WO2020146731A1 (en) Compositions and methods for inhibiting vascular endothelial growth factor
AU2020201145A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200120

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220314

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220323

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220408

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220411

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220527

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220531

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241015